ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares of the company's stock, valued at $5,526,799.20. This trade represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Meredith Cook also recently made the following trade(s):
- On Thursday, March 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00.
- On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.54, for a total value of $23,816.00.
ANI Pharmaceuticals Stock Performance
Shares of NASDAQ ANIP traded up $0.01 during mid-day trading on Friday, hitting $69.21. The company had a trading volume of 299,660 shares, compared to its average volume of 271,192. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.48. The firm has a market cap of $1.51 billion, a P/E ratio of -125.84 and a beta of 0.49. The business's 50-day simple moving average is $63.26 and its 200-day simple moving average is $59.44. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of institutional investors have recently bought and sold shares of ANIP. US Bancorp DE lifted its holdings in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares during the period. KBC Group NV boosted its holdings in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after purchasing an additional 600 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after purchasing an additional 881 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $166,000. Finally, HighTower Advisors LLC acquired a new stake in ANI Pharmaceuticals in the 3rd quarter valued at $222,000. Institutional investors and hedge funds own 76.05% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. StockNews.com upgraded shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday. Finally, Guggenheim reaffirmed a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $79.75.
View Our Latest Stock Analysis on ANIP
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Stories
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
